DermaSensor vs SimpleSense
DermaSensor works in a primary care exam room and Nanowear works in a patient's home. A primary care physician rents the handheld DermaSensor for lesions already judged suspicious. A heart failure or cardiology program issues Nanowear's cloth garment, which sends multi-sensor data to cloud analytics and estimates blood pressure without a cuff.
Nanowear has four 510(k) clearances on openFDA, while its homepage says "FDA approved". A 2025 study of 303 subjects over four weeks, written by Nanowear authors, validated the blood pressure estimate internally and asks for external validation. Third-party sources put its funding at $1.52M (Tracxn) and under $5 million (ZoomInfo). DermaSensor announced a $16M Series B on October 2, 2025 and reports $43M in total investment. Its evidence page lists multicenter prospective and multi-reader studies, and its FAQ says EHR integration will come over time.
Decision support · Reviewed November 2, 2026
DermaSensor
by DermaSensor · founded 2009
Handheld spectroscopy device giving primary care physicians an AI score on skin lesions already judged suspicious.
SimpleSense
by Nanowear · founded 2014
Cloth wearable with 510(k) cleared AI cloud analytics for remote cardiac monitoring and cuffless blood pressure.
When to pick each one
DermaSensor
- $16M Series B in October 2025
- Primary care handheld, patients 40 and older
SimpleSense
- Cloth garment, cuffless blood pressure estimate
- Four 510(k) clearances, K161431 through K232053
Score
Each row shows points earned of points available under the published rubric.
DermaSensor
49of 100
SimpleSense
49of 100
| Dimension | DermaSensor | SimpleSense | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 12 / 12 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 5.6 | 0 / 5.6 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 0 / 4.8 | 0 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 14.7 / 21 | 0 |
| RCT / meta-analysis / systematic review | 4.5 / 9 | 4.5 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
DermaSensor
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No published price for an outright purchase. Monthly rental subscription, one-year device use agreement with try-and-return option. |
SimpleSense
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
DermaSensor
FDA decisions
DEN230008 (opens in new tab)De Novo2024-01-12
DermaSensor
Peer-reviewed
3 PubMed records name DermaSensor.
- Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA. (opens in new tab)
- Enhancing Diagnostic Precision in Primary Care: A Multireader Multicase (MRMC) Study of an AI-Powered Handheld Elastic Scattering Spectroscopy Device for Informed Referral Decisions in Melanoma Evaluation. (opens in new tab)
- Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. (opens in new tab)
SimpleSense
FDA decisions
K232053 (opens in new tab)510(k)2023-12-08
SimpleSense-BP, SimpleSense-BP Software Application
K212160 (opens in new tab)510(k)2021-09-22
SimpleSENSE Platform
K201669 (opens in new tab)510(k)2020-11-06
SimpleSENSE
K161431 (opens in new tab)510(k)2016-11-30
SimplECG
Peer-reviewed
3 PubMed records name SimpleSense.
- Multiparametric cloth-based wearable, SimpleSense, estimates blood pressure. (opens in new tab)
- Development and Internal Validation of an AI-Enabled Cuff-less, Non-invasive Continuous Blood Pressure Monitor Across All Classes of Hypertension. (opens in new tab)
- Nanotechnology and Artificial Intelligence: An Emerging Paradigm for Postoperative Patient Care. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | DermaSensor | SimpleSense |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2009 | 2014 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.